BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $103,197.25 in Stock


Share on StockTwits

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 2,825 shares of the firm’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $36.53, for a total transaction of $103,197.25. Following the transaction, the chief marketing officer now owns 80,029 shares of the company’s stock, valued at $2,923,459.37. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Todd Berard also recently made the following trade(s):

  • On Friday, March 26th, Todd Berard sold 2,120 shares of BioLife Solutions stock. The stock was sold at an average price of $35.01, for a total transaction of $74,221.20.
  • On Tuesday, March 16th, Todd Berard sold 6,160 shares of BioLife Solutions stock. The stock was sold at an average price of $36.72, for a total transaction of $226,195.20.
  • On Thursday, February 18th, Todd Berard sold 1,882 shares of BioLife Solutions stock. The stock was sold at an average price of $40.67, for a total transaction of $76,540.94.
  • On Tuesday, February 16th, Todd Berard sold 12,324 shares of BioLife Solutions stock. The stock was sold at an average price of $44.48, for a total transaction of $548,171.52.

Shares of BLFS stock opened at $34.86 on Thursday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -47.75, a price-to-earnings-growth ratio of 50.41 and a beta of 1.55. BioLife Solutions, Inc. has a fifty-two week low of $8.88 and a fifty-two week high of $47.97. The firm’s 50 day moving average price is $37.99 and its two-hundred day moving average price is $36.34.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Sunday, March 21st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04). BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. The business had revenue of $14.73 million for the quarter, compared to analyst estimates of $13.43 million. On average, research analysts anticipate that BioLife Solutions, Inc. will post 0.01 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of BioLife Solutions by 5.7% during the fourth quarter. Victory Capital Management Inc. now owns 75,447 shares of the medical equipment provider’s stock worth $3,010,000 after purchasing an additional 4,039 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of BioLife Solutions by 63.9% during the third quarter. JPMorgan Chase & Co. now owns 119,245 shares of the medical equipment provider’s stock worth $3,418,000 after purchasing an additional 46,474 shares in the last quarter. BlackRock Inc. lifted its position in shares of BioLife Solutions by 82.9% during the third quarter. BlackRock Inc. now owns 1,111,337 shares of the medical equipment provider’s stock worth $32,162,000 after purchasing an additional 503,659 shares in the last quarter. Brookfield Asset Management Inc. acquired a new position in shares of BioLife Solutions during the fourth quarter worth $586,000. Finally, Jennison Associates LLC acquired a new position in shares of BioLife Solutions during the fourth quarter worth $17,934,000. 67.66% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on BLFS. Maxim Group lifted their price target on shares of BioLife Solutions from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, March 23rd. KeyCorp lifted their price target on shares of BioLife Solutions from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 29th. Northland Securities boosted their target price on shares of BioLife Solutions from $35.00 to $55.00 in a report on Monday, December 28th. Stephens boosted their target price on shares of BioLife Solutions from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, March 23rd. Finally, Zacks Investment Research upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, January 6th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $45.10.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Article: Momentum Indicators

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.